The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The EBUS is designed to support the diagnosis and staging of various lung disorders
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It affects up to 10 per cent of women of reproductive age around the world
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
These melas serve as platforms to attract thousands of people to avail quality healthcare services along with essential medicines and diagnostic services
Subscribe To Our Newsletter & Stay Updated
